TESARO Inc (TSRO) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-1.28 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.42. Analysts had a consensus of $-1.70. The company posted revenue of $36.60 million in the period, compared to analysts expectations of $2.48 million. During the same quarter in the previous year, the company posted $-1.51 EPS.
Many Wall Street Analysts have commented on TESARO Inc. Robert W. Baird Initiated TESARO Inc on Jul 19, 2016 to “Outperform”, Price Target of the shares are set at $105.Company shares were Reiterated by Mizuho on Jul 5, 2016 to “Buy”, Firm has raised the Price Target to $ 94 from a previous price target of $67 .TESARO Inc was Downgraded by Jefferies to ” Hold” on Jun 30, 2016.
TESARO Inc opened for trading at $95.3 and hit $96.71 on the upside on Tusday, eventually ending the session at $95.6, with a gain of 0.47% or 0.45 points. The heightened volatility saw the trading volume jump to 7,48,613 shares. Company has a market cap of $4,383 M.
In a different news, on Jul 1, 2016, Jeffrey H. Hanke (Executive VP, R&D and CSO) sold 12,500 shares at $74.02 per share price. According to the SEC, on Jun 14, 2016, Edward C English (VP of Finance & Administration) sold 7,000 shares at $41.21 per share price. On Mar 18, 2016, Beth C Seidenberg (director) purchased 1,420,858 shares at $35.19 per share price, according to the Form-4 filing with the securities and exchange commission.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.